Artificial Intelligence in Clinical Trials: Transforming Patient Recruitment, Data Management, and Drug Development Processes

Clicks: 2
ID: 309213
2024
Free PDF
Article Quality & Performance Metrics
Overall Quality
Not rated
Combines reader engagement with the AI quality analysis. This article has not been analysed, so there is no overall score — reader engagement is measured and shown alongside.
AI Quality Assessment
Not analyzed
Readership in this journal
Emerging

Ranked #143 of 153 articles by views in International Journal of Pharmaceutical Drug Design (IJPDD)

Most read Least read

Bar heights use a square-root scale. Only the 120 most-read articles are drawn; the journal has 153 in total.

Mint this article as an NFT
Not yet minted

Create a permanent, verifiable on-chain record of this article on the Scimatic Network. The NFT is held in your Journament account, and you can withdraw it to your own wallet at any time.

5 SUSD one-off · no wallet required
Sign in to mint
Abstract
The clinical trials are important for the development of medical science since it becomes easier to test novel drugs, medical equipment, and even new methods in the treatment of a person. Only 10% of these studies were able to complete the entire process-from original drug design to post-marketing surveillance, which is slightly worrying. This low completion rate seriously jeopardizes the overall sustainability of clinical research and public health and healthcare economics. Increasing study designs and costs, along with other related difficulties in patient recruitment and data management, also work to worsen this problem. In this respect, AI has become a really powerful instrument that can revolutionize several aspects related to clinical trials. Thus, to gauge the effectiveness of AI in the sphere of patient recruitment efficiency, and the accuracy of data management along with meeting deadlines for the development of drugs, this paper would be carried out by a mixed-methods approach. The paper illustrates considerable achievements in the fields associated with AI technologies through qualitative views of experts along with the quantitative analysis of key indicators. According to the findings, AI has decreased input error in data by 25%, cut average development time for medication by 22%, and reduced total identification of patients by 30%. Besides, AI has also been enhanced to predict the efficacy of drugs with the precision of 13%. These outcomes therefore highlight how AI can accelerate the procedures of clinical trials and increase participant diversity, which may, in the long run, influence the outcome of the trail. This may thus open doors for health breakthroughs to be more efficient and timely delivered.
Reference Key
imported_1761926675_6904de13b249d Use this key to autocite in the manuscript while using SciMatic Manuscript Manager or Thesis Manager
Authors Krati Dhakad*, Pranjali Bawane, Amit Verma, Akanksha, Aiman Sifat, Swagatama Ghosh
Journal International Journal of Pharmaceutical Drug Design (IJPDD)
Year 2024
DOI
10.62896/ijpdd.1.11.1
URL
https://ijpdd.org/index.php/files/article/view/163
Keywords Keywords not found

Citations

No citations found. To add a citation, contact the admin at info@scimatic.org

Comments

No comments yet. Be the first to comment on this article.